RNS Number : 4139O Renalytix PLC 10 June 2022     Renalytix plc ("Renalytix" or the "Company")   1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX TM Risk Stratification  in Stage 1 to 3 Diabetic Kidney Disease Patients   Late-breaking data presented at American

RNS Number : 0740O Renalytix PLC 08 June 2022       Renalytix to Present at 42 nd Annual William Blair Growth Stock Conference   NEW YORK and SALT LAKE CITY , June 8, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42 nd Annual William Blair Growth

RNS Number : 6870N Renalytix PLC 06 June 2022   Renalytix plc ("Renalytix" or the "Company")   Renalytix held Two Data Presentations on KidneyIntelX at American Diabetes Association 82 nd Scientific Sessions®   Real-world clinical utility in 1,112 patients tested with   KidneyIntelX KidneyIntelX

RNS Number : 6872N Renalytix PLC 06 June 2022   Renalytix plc ("Renalytix" or the "Company")   KidneyIntelX TM Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort   Data shared in oral presentation at American

RNS Number : 9425J Renalytix PLC 29 April 2022   Renalytix plc   (" Renalytix " or the " Company ")     Total voting rights   NEW YORK and SALT LAKE CITY , 29 April, 2022 - Renalytix (LSE: RENX) announces that t he Company's total issued share capital consists of 74,760,432 shares of 0.25 pence

RNS Number : 9726I Renalytix PLC 22 April 2022     Renalytix plc ("Renalytix" or the "Company")   Grant of Share Options   New York and SALT LAKE CITY , April  22, 2022   -   Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Remuneration Committee has agreed to issue options over a total

RNS Number : 7218H Renalytix PLC 08 April 2022   Renalytix plc ("Renalytix" or the "Company")   Issue of shares   NEW YORK and SALT LAKE CITY , 8 April, 2022 - Renalytix Plc   (NASDAQ: RNLX) (LSE: RENX)   announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new

RNS Number : 7737H Renalytix PLC 08 April 2022   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR

RNS Number : 7325G Renalytix PLC 31 March 2022   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR

RNS Number : 6807G Renalytix PLC 31 March 2022       Renalytix plc ("Renalytix" or the "Company")   Half Year Report   LONDON and SALT LAKE CITY , March 31, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE : RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing